Skip to main content
. 2020 Mar 13;19:100159. doi: 10.1016/j.jctube.2020.100159

Table 2.

MTBC positivity and RR tested in sputum samples from previously treated suspected MDR-PTB cases using Xpert MTB/RIF during 2016–2018.

Total sputum samples Xpert MTB/RIF
3893 MTBC Pos (1936/3893, 49.73%)
RS RR
1422/3893 (36.53%) 514/3893 (13.20%)

RS: Rifampicin sensitive; RR: Rifampicin resistant.